Clozapine and the risk of haematological malignancies
Lancet Psychiatry
.
2022 Jul;9(7):538-539.
doi: 10.1016/S2215-0366(22)00149-3.
Authors
Peter Fj Schulte
1
,
Dan Cohen
2
,
Selene Rt Veerman
2
,
Bert Bakker
3
,
Jan Pam Bogers
4
Affiliations
1
Mental Health Service Noord-Holland-Noord, Alkmaar, Netherlands; Dutch Clozapine Collaboration Group, Oegstgeest, Netherlands. Electronic address: r.schulte@ggz-nhn.nl.
2
Mental Health Service Noord-Holland-Noord, Alkmaar, Netherlands; Dutch Clozapine Collaboration Group, Oegstgeest, Netherlands.
3
Dutch Clozapine Collaboration Group, Oegstgeest, Netherlands.
4
Dutch Clozapine Collaboration Group, Oegstgeest, Netherlands; High Care Psychiatric Clinic, Mental Health Service Rivierduinen, Leiden, Netherlands.
PMID:
35717957
DOI:
10.1016/S2215-0366(22)00149-3
No abstract available
Publication types
Letter
Comment
MeSH terms
Antipsychotic Agents* / adverse effects
Clozapine* / adverse effects
Hematologic Neoplasms* / drug therapy
Humans
Substances
Antipsychotic Agents
Clozapine